問卷

TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Nephrology

Division of General Internal Medicine

更新時間:2023-11-28

吳建興Wu, Chien-Hsing
  • Principal Investigator
  • Clinical Trial Experience (year)
  • chienhsingwu@gmail.com

篩選

List

29Cases

2023-12-01 - 2029-06-30

Phase III

Active
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults with IgA Nephropathy (The BEYOND Study)
  • Condition/Disease

    Adults with IgA Nephropathy

  • Test Drug

    injection

Participate Sites
8Sites

Recruiting8Sites

2023-12-01 - 2029-06-30

Phase III

Active
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study)
  • Condition/Disease

    IgA Nephropathy 、Immunoglobulin A Nephropathy

  • Test Drug

    皮下注射劑

Participate Sites
8Sites

Recruiting8Sites

2023-06-30 - 2030-12-31

Phase III

Active
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
7Sites

Recruiting7Sites

2024-09-30 - 2028-11-30

Phase III

Active
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF POVETACICEPT IN ADULTS WITH IMMUNOGLOBULIN A NEPHROPATHY (RAINIER)
  • Condition/Disease

    IMMUNOGLOBULIN A NEPHROPATHY

  • Test Drug

    injection

Participate Sites
8Sites

Recruiting8Sites

2025-06-30 - 2029-04-30

Phase II

Not yet recruiting
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
  • Condition/Disease

    Complement-Mediated Kidney Disease

  • Test Drug

    Injection

Participate Sites
2Sites

Recruiting2Sites

2020-03-31 - 2022-11-30

Phase II

Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants with Immunoglobulin A (IgA) Nephropathy
  • Condition/Disease

    Immunoglobulin A (IgA) Nephropathy

  • Test Drug

    VIS649

Participate Sites
6Sites

Not yet recruiting2Sites

Recruiting3Sites

Study ended1Sites

2021-11-01 - 2026-02-28

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-03-19 - 2025-07-15

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2026-01-26 - 2031-01-31

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2021-10-01 - 2029-04-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

1 2 3